VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Subjects must                                      │ Subjects must                                      │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Be able to give valid informed consent             │ Be able to give valid informed consent             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Be 18 55 years of age                              │ Be 18 55 years of age                              │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Justification: Many neural processes change with   │ Justification: Many neural processes change with   │     100 │
│ age, and these changes could introduce unwanted    │ age, and these changes could introduce unwanted    │         │
│ variability in both behavioral and MRI signals. In │ variability in both behavioral and MRI signals. In │         │
│ addition, the risk of difficult-to-detect medical  │ addition, the risk of difficult-to-detect medical  │         │
│ abnormalities such as silent cerebral infarcts     │ abnormalities such as silent cerebral infarcts     │         │
│ increases with age                                 │ increases with age                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Screening tool: History. Government-issued forms   │ Screening tool: History. Government-issued forms   │     100 │
│ of identification (e.g. driver s license, birth    │ of identification (e.g. driver s license, birth    │         │
│ certificate) will be required when participant     │ certificate) will be required when participant     │         │
│ appears to be out of age range                     │ appears to be out of age range                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Be in good health                                  │ Be in good health                                  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Justification: Many illnesses may alter neural     │ Justification: Many illnesses may alter neural     │     100 │
│ functioning as well as fMRI signals                │ functioning as well as fMRI signals                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Right-handed                                       │ Right-handed                                       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Justification: Using right-handed individuals will │ Justification: Using right-handed individuals will │     100 │
│ reduce variability in BOLD MRI data                │ reduce variability in BOLD MRI data                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Screening tool: Edinburgh Handedness Inventory     │ Screening tool: Edinburgh Handedness Inventory     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Justification: Subjects must be able to perform a  │ Justification: Subjects must be able to perform a  │     100 │
│ cognitively challenging task to a high standard    │ cognitively challenging task to a high standard    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Screening tool: Wechsler Abbreviated Scale of      │ Screening tool: Wechsler Abbreviated Scale of      │     100 │
│ Intelligence                                       │ Intelligence                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Personal history of stroke, brain lesions,         │ Personal history of stroke, brain lesions,         │     100 │
│ previous neurosurgery, any personal history of     │ previous neurosurgery, any personal history of     │         │
│ seizure or fainting episode of unknown cause, or   │ seizure or fainting episode of unknown cause, or   │         │
│ head trauma resulting in loss of consciousness,    │ head trauma resulting in loss of consciousness,    │         │
│ lasting over 30 minutes or with sequela lasting    │ lasting over 30 minutes or with sequela lasting    │         │
│ longer than two days                               │ longer than two days                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Justification: Stroke or head trauma can lower the │ Justification: Stroke or head trauma can lower the │     100 │
│ seizure threshold, and are therefore contra-       │ seizure threshold, and are therefore contra-       │         │
│ indications for TMS. Fainting episodes or syncope  │ indications for TMS. Fainting episodes or syncope  │         │
│ of unknown cause could indicate an undiagnosed     │ of unknown cause could indicate an undiagnosed     │         │
│ condition associated with seizures                 │ condition associated with seizures                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Screening tool: TMS adult safety questionnaire,    │ Screening tool: TMS adult safety questionnaire,    │     100 │
│ Medical History                                    │ Medical History                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ First-degree family history of any neurological    │ First-degree family history of any neurological    │     100 │
│ disorder with a potentially hereditary basis,      │ disorder with a potentially hereditary basis,      │         │
│ including migraines, epilepsy, or multiple         │ including migraines, epilepsy, or multiple         │         │
│ sclerosis                                          │ sclerosis                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Justification: Neurological disorders can lower    │ Justification: Neurological disorders can lower    │     100 │
│ the seizure threshold, and are therefore contra-   │ the seizure threshold, and are therefore contra-   │         │
│ indications for TMS. First-degree family history   │ indications for TMS. First-degree family history   │         │
│ of certain neurological disorders with a           │ of certain neurological disorders with a           │         │
│ hereditary component increases the risk of the     │ hereditary component increases the risk of the     │         │
│ subject having an undiagnosed condition that is    │ subject having an undiagnosed condition that is    │         │
│ associated with lowered seizure threshold          │ associated with lowered seizure threshold          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Screening tool: TMS adult safety screening,        │ Screening tool: TMS adult safety screening,        │     100 │
│ Medical History                                    │ Medical History                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Cardiac pacemakers, neural stimulators,            │ Cardiac pacemakers, neural stimulators,            │     100 │
│ implantable defibrillator, implanted medication    │ implantable defibrillator, implanted medication    │         │
│ pumps, intracardiac lines, or acute, unstable      │ pumps, intracardiac lines, or acute, unstable      │         │
│ cardiac disease, with intracranial implants (e.g.  │ cardiac disease, with intracranial implants (e.g.  │         │
│ aneurysm clips, shunts, stimulators, cochlear      │ aneurysm clips, shunts, stimulators, cochlear      │         │
│ implants, or electrodes) or any other metal object │ implants, or electrodes) or any other metal object │         │
│ within or near the head that precludes MRI         │ within or near the head that precludes MRI         │         │
│ scanning                                           │ scanning                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Justification: Any metal around the head is a      │ Justification: Any metal around the head is a      │     100 │
│ contraindication for both MRI and TMS, as both     │ contraindication for both MRI and TMS, as both     │         │
│ methods involve exposure to a relatively strong    │ methods involve exposure to a relatively strong    │         │
│ magnetic field                                     │ magnetic field                                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Screening tool: TMS adult safety screening, MRI    │ Screening tool: TMS adult safety screening, MRI    │     100 │
│ safety screening, Medical History                  │ safety screening, Medical History                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Noise-induced hearing loss or tinnitus             │ Noise-induced hearing loss or tinnitus             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Justification: individuals with noise-induced      │ Justification: individuals with noise-induced      │     100 │
│ hearing problems may be particularly vulnerable to │ hearing problems may be particularly vulnerable to │         │
│ the acoustic noise generated by TMS and MRI        │ the acoustic noise generated by TMS and MRI        │         │
│ equipment                                          │ equipment                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Screening tools: TMS adult safety screening        │ Screening tools: TMS adult safety screening        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current use (any use in the past 4 weeks, chronic  │ Current use (any use in the past 4 weeks, chronic  │     100 │
│ use within 6 past six months) of any               │ use within 6 past six months) of any               │         │
│ investigational drug or of any medications with    │ investigational drug or of any medications with    │         │
│ psychotropic, anti or pro-convulsive action        │ psychotropic, anti or pro-convulsive action        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Justification: The use of certain medications or   │ Justification: The use of certain medications or   │     100 │
│ drugs can lower seizure threshold and is therefore │ drugs can lower seizure threshold and is therefore │         │
│ contra-indicated for TMS                           │ contra-indicated for TMS                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Screening tools: MRI safety screening              │ Screening tools: MRI safety screening              │     100 │
│ questionnaire, Medical history, Medical            │ questionnaire, Medical history, Medical            │         │
│ Assessments: Urine toxicology analyzes for         │ Assessments: Urine toxicology analyzes for         │         │
│ presence of a broad range of prescription and      │ presence of a broad range of prescription and      │         │
│ nonprescription drugs                              │ nonprescription drugs                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Lifetime history of major depressive disorder,     │ Lifetime history of major depressive disorder,     │     100 │
│ schizophrenia, bipolar disorder, mania, or         │ schizophrenia, bipolar disorder, mania, or         │         │
│ hypomania                                          │ hypomania                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Justification: The population of interest here is  │ Justification: The population of interest here is  │     100 │
│ a healthy control population with no psychiatric   │ a healthy control population with no psychiatric   │         │
│ disorders. In subjects with depression, bipolar    │ disorders. In subjects with depression, bipolar    │         │
│ disorder, mania or hypomania, there is a small     │ disorder, mania or hypomania, there is a small     │         │
│ chance that TMS can trigger (hypo)manic symptoms   │ chance that TMS can trigger (hypo)manic symptoms   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Justification: The population of interest here is  │ Justification: The population of interest here is  │     100 │
│ a healthy control population with no substance use │ a healthy control population with no substance use │         │
│ disorder. Current use of illicit substances could  │ disorder. Current use of illicit substances could  │         │
│ impact on seizure threshold and is therefore       │ impact on seizure threshold and is therefore       │         │
│ contra-indicated for TMS                           │ contra-indicated for TMS                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Screening tools: SCID Screen Patient               │ Screening tools: SCID Screen Patient               │     100 │
│ Questionnaire. Potential diagnoses will be further │ Questionnaire. Potential diagnoses will be further │         │
│ evaluated by a counsellor, Drug Use Survey (DUS),  │ evaluated by a counsellor, Drug Use Survey (DUS),  │         │
│ Substance Use Disorder Evaluation, Medical         │ Substance Use Disorder Evaluation, Medical         │         │
│ Assessments: urine qualitative drug screen is      │ Assessments: urine qualitative drug screen is      │         │
│ performed for methadone, benzodiazepines, cocaine, │ performed for methadone, benzodiazepines, cocaine, │         │
│ amphetamine/methamphetamine, opiates,              │ amphetamine/methamphetamine, opiates,              │         │
│ barbiturates, and tetrahydrocannabinol             │ barbiturates, and tetrahydrocannabinol             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Have met DSM V criteria for moderate to severe     │ Have met DSM V criteria for moderate to severe     │     100 │
│ substance use disorder (excluding nicotine,        │ substance use disorder (excluding nicotine,        │         │
│ alcohol and cannabis) in the past, or have met DSM │ alcohol and cannabis) in the past, or have met DSM │         │
│ V criteria for moderate to severe substance use    │ V criteria for moderate to severe substance use    │         │
│ disorder for cannabis or alcohol in the past 5     │ disorder for cannabis or alcohol in the past 5     │         │
│ years                                              │ years                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Justification: the population of interest here is  │ Justification: the population of interest here is  │     100 │
│ a healthy control population with no present or    │ a healthy control population with no present or    │         │
│ past substance use disorder                        │ past substance use disorder                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Screening tools: SCID Screen Patient               │ Screening tools: SCID Screen Patient               │     100 │
│ Questionnaire. Potential diagnoses will be further │ Questionnaire. Potential diagnoses will be further │         │
│ evaluated by a counselor. Drug Use Survey (DUS),   │ evaluated by a counselor. Drug Use Survey (DUS),   │         │
│ Substance Use Disorder Evaluation                  │ Substance Use Disorder Evaluation                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of myocardial infarction, angina,          │ History of myocardial infarction, angina,          │     100 │
│ congestive heart failure, cardiomyopathy, stroke   │ congestive heart failure, cardiomyopathy, stroke   │         │
│ or transient ischemic attack, or any heart         │ or transient ischemic attack, or any heart         │         │
│ condition currently under medical care             │ condition currently under medical care             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Justifications: the risk of TMS for individuals    │ Justifications: the risk of TMS for individuals    │     100 │
│ with a heart condition is unknown                  │ with a heart condition is unknown                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Screening tool: physical assessment (EKG), medical │ Screening tool: physical assessment (EKG), medical │     100 │
│ history                                            │ history                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnant women or women with reproductive          │ Pregnant women or women with reproductive          │     100 │
│ potential who are sexually active and not using an │ potential who are sexually active and not using an │         │
│ acceptable form of contraception                   │ acceptable form of contraception                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Justification: it is unknown whether TMS poses a   │ Justification: it is unknown whether TMS poses a   │     100 │
│ risk to fetuses                                    │ risk to fetuses                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Screening tool: Medical assessments (urine         │ Screening tool: Medical assessments (urine         │     100 │
│ pregnancy test) at the beginning of each visit     │ pregnancy test) at the beginning of each visit     │         │
│ that involves TMS or MRI                           │ that involves TMS or MRI                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Justification: Subjects should be able to perform  │ Justification: Subjects should be able to perform  │     100 │
│ cognitive tasks to a high degree of accuracy, both │ cognitive tasks to a high degree of accuracy, both │         │
│ in the MRI scanner and outside the scanner.        │ in the MRI scanner and outside the scanner.        │         │
│ Subjects with ADHD/LD may engage different neural  │ Subjects with ADHD/LD may engage different neural  │         │
│ circuitry even if they can perform the tasks       │ circuitry even if they can perform the tasks       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Screening tool: Wechsler Abbreviated Scale of      │ Screening tool: Wechsler Abbreviated Scale of      │     100 │
│ Intelligence, Medical history, Adult ADHD Self-    │ Intelligence, Medical history, Adult ADHD Self-    │         │
│ Report Scale                                       │ Report Scale                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participation in an rTMS session less than two     │ Participation in an rTMS session less than two     │     100 │
│ weeks ago                                          │ weeks ago                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Justification: in order to limit exposure to TMS,  │ Justification: in order to limit exposure to TMS,  │     100 │
│ we will not enroll subjects who have received TMS  │ we will not enroll subjects who have received TMS  │         │
│ less than two weeks ago                            │ less than two weeks ago                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Screening tool: TMS safety screening questionnaire │ Screening tool: TMS safety screening questionnaire │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Screening tools: Medical Assessment, Medical       │ Screening tools: Medical Assessment, Medical       │      89 │
│ History and Physical Examination. Medical          │ History and Physical Examination. Medical          │         │
│ assessments include: Vital Signs, EKG, oral HIV    │ assessments include: Vital Signs, EKG, oral HIV    │         │
│ test, height/weight measurements, urinalysis and   │ test, height/weight measurements, urinalysis and   │         │
│ blood sample. Tests on the blood sample include    │ blood sample. Tests on the blood sample include    │         │
│ complete blood count (CBC), complete metabolic     │ CBC, complete metabolic profile, TSH, ESR, STS and │         │
│ profile, thyroid-stimulating hormone (TSH),        │ HIV (if needed to confirm a positive salivary test │         │
│ erythrocyte sedimentation rate (ESR), Serologic    │ for HIV). The following individual laboratory      │         │
│ Test For Syphilis (STS) and HIV (if needed to      │ results will independently disqualify individuals: │         │
│ confirm a positive salivary test for HIV). The     │ Cholesterol >250 mg/dl, Hemoglobin < 10.5 g/dl,    │         │
│ following individual laboratory results will       │ WBC < 2400/microl, LFTs > 3Xnormal, HCG positive,  │         │
│ independently disqualify individuals: Cholesterol  │ Casual serum glucose > 200 mg/dl, Urine protein >  │         │
│ \>250 mg/dl, Hemoglobin \< 10.5 g/dl, white blood  │ 1+. The MAI will retain discretion to exclude at   │         │
│ cell count (WBC) \< 2400/microl, liver function    │ less extreme values, depending on the clinical     │         │
│ tests (LFTs) \> 3x normal, Human chorionic         │ presentation. (Serum glucose over 140 mg/dl will   │         │
│ gonadotropin (HCG) positive, Casual serum glucose  │ be followed up with a fasting serum glucose        │         │
│ \> 200 mg/dl, Urine protein \> 1+. The medically   │ assessment. Those with fasting glucose below 100   │         │
│ accountable investigator (MAI) will retain         │ mg/dl may be considered for the protocol. Others   │         │
│ discretion to exclude at less extreme values,      │ will be rejected and referred for work-up.) MAI    │         │
│ depending on the clinical presentation. (Serum     │ will make the final judgment on any questionable   │         │
│ glucose over 140 mg/dl will be followed up with a  │ lab results                                        │         │
│ fasting serum glucose assessment. Those with       │                                                    │         │
│ fasting glucose below 100 mg/dl may be considered  │                                                    │         │
│ for the protocol. Others will be rejected and      │                                                    │         │
│ referred for work-up.) MAI will make the final     │                                                    │         │
│ judgment on any questionable lab results           │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Meet current Diagnostic and Statistical Manual     │ Meet current DSM V criteria for moderate to severe │      92 │
│ (DSM) V criteria for moderate to severe substance  │ substance use disorder (excluding nicotine), smoke │         │
│ use disorder (excluding nicotine), smoke daily, or │ daily, or urine toxicology positive for any        │         │
│ urine toxicology positive for any illicit          │ illicit substance inconsistent with history given  │         │
│ substance inconsistent with history given          │                                                    │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Must have maximum age of 55 Years                  │ Be 18 55 years of age                              │      37 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years                  │ Be in good health                                  │      40 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of learning disability or current          │ History of learning disability or current ADHD     │      68 │
│ attention deficit hyperactivity disorder (ADHD)    │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Screening tools: Structured Clinical Interview for │ Screening tools: SCID Screen Patient               │      70 │
│ the Diagnostic and Statistical Manual for Mental   │ Questionnaire. Potential diagnoses will be further │         │
│ Disorders (SCID) Screen Patient Questionnaire.     │ evaluated by a counsellor                          │         │
│ Potential diagnoses will be further evaluated by a │                                                    │         │
│ counsellor                                         │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Estimated intelligence quotient (IQ) greater than  │ Estimated IQ greater than or equal to 85           │      77 │
│ or equal to 85                                     │                                                    │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only CHIA has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ History of learning disability or current          │ History of learning disability or current ADHD     │      68 │
│ attention deficit hyperactivity disorder (ADHD)    │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Estimated intelligence quotient (IQ) greater than  │ Estimated IQ greater than or equal to 85           │      77 │
│ or equal to 85                                     │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Screening tools: SCID Screen Patient               │ Screening tools: SCID Screen Patient               │      79 │
│ Questionnaire. Potential diagnoses will be further │ Questionnaire. Potential diagnoses will be further │         │
│ evaluated by a counselor. Drug Use Survey (DUS),   │ evaluated by a counsellor                          │         │
│ Substance Use Disorder Evaluation                  │                                                    │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 97
Average Levenshtein Ratio of individual lines: 94.49090909090908
OverAll Ratio: 95.74545454545455
